Impact of the modulator elexacaftor/tezacaftor/ivacaftor (ETI) on the complexity of prescriptions and the clinical stage of children and adolescents with cystic fibrosis. Research, Society and Development, [S. l.], v. 15, n. 1, p. e7715150550, 2026. DOI: 10.33448/rsd-v15i1.50550. Disponível em: https://rsdjournal.org/rsd/article/view/50550. Acesso em: 3 feb. 2026.